Coming from a background where there is a lot of morbidity and mortality due to cancer it encourages me and motivates me to do better. My name is Dr. Allan Njau. I’m a practicing pathologist in Nairobi, Kenya. And now I’m based at the Aga Khan University Hospital. I’m coming from a background where we do have a very high incidence of cancer and also that is accompanied by a higher mortality rate. And of course, we all are looking for ways and means to improve the care and the outcome for cancer patients. And so one of the things I think will be critical for us is to look for ways and means to have sustainable programs for molecular testing that would really help in improving diagnostics in Kenya. One of the platforms I’ve been learning and working on is the QIAGEN NGS solution. What I really like about the platform is that it’s quite focused and looks at certain specific and actionable mutations in genes which would have a very great impact. So, I’ve be learning also the QCI analysis platform. Right from the NGS solution to variant calling to reporting is all in one system. And so it gives you confidence that the instruments you’re dealing with in the wet lab is very well connected and works perfectly with the bioinformatics pipeline and the reporting solution. So, I think that all of us in the healthcare sector and other key stakeholders have to wake up to this idea that molecular testing is important for cancer care. It does improve care, it does improve outcomes for cancer patients.